SCHEMBL2320146

SCHEMBL2320146

CC(C)(O)c1ccc(-n2cnc(-c3c(-c4ccc(F)cc4)noc3C(F)(F)F)c2)nc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.42
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
GABRA5 P31644 8/20 0.35
FFAR4 Q5NUL3 2/20 0.34
TGFBR1 P36897 1/20 0.33
LMNA P02545 2/20 0.32
TP53 P04637 2/20 0.32
MAPT P10636 2/20 0.32
THRB P10828 1/20 0.32
RAB9A P51151 1/20 0.31
MAPK9 P45984 1/20 0.31
MAPK10 P53779 1/20 0.31
MAPK11 Q15759 1/20 0.31
MAPK14 Q16539 1/20 0.31
TNKS O95271 1/20 0.31
PARP1 P09874 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2319935 0.87 PTGS2 (0.44) PTGS2ESR1ESR2GABRA5FFAR4
SCHEMBL2319661 0.84 GABRA5 (0.44) PTGS2ESR1ESR2GABRA5FFAR4
SCHEMBL2320346 0.82 ESR1 (0.46) PTGS2ESR1ESR2GABRA5FFAR4
SCHEMBL2318101 0.82 PTGS2 (0.41) PTGS2ESR1ESR2GABRA5FFAR4
SCHEMBL2321025 0.82 GABRA5 (0.56) PTGS2GABRA5LMNA
SCHEMBL2318109 0.80 PTGS2 (0.46) PTGS2ESR1ESR2FFAR4LMNA
SCHEMBL2317390 0.78 GABRA5 (0.59) GABRA5
SCHEMBL2317488 0.77 GABRA5 (0.58) GABRA5
SCHEMBL2322913 0.77 GABRA5 (0.61) PTGS2GABRA5
SCHEMBL2319340 0.76 GABRA5 (0.61) GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170873-B1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP claimed
US-7851469-B2 Isoxazole-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-14 US claimed
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-01-01 US claimed
EP-2170873-B1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
US-7851469-B2 Isoxazole-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-14 US disclosed
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES GABRA5, GABRA1, GABRA4 PTGS2 2317/4885ESR1 721/4885ESR2 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.